Get the Stockscreener App
3.38
3.68%
0.12
Pre-market:
3.27
-0.11
-3.25%
Xenetic Biosciences Inc stock is traded at $3.38, with a volume of 6,701.
It is up +3.68% in the last 24 hours and up +20.38% over the past month.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.
See More
Previous Close:
$3.26
Open:
$3.25
24h Volume:
6,701
Relative Volume:
0.28
Market Cap:
$7.74M
Revenue:
$2.98M
Net Income/Loss:
$-2.68M
P/E Ratio:
-2.092
EPS:
-1.6157
Net Cash Flow:
$-2.29M
1W Performance:
+10.82%
1M Performance:
+20.38%
6M Performance:
-29.73%
1Y Performance:
+36.29%
1-Day Range:
$3.23
$3.40
1-Week Range:
$2.9452
$3.40
52-Week Range:
$1.90
$13.93
Xenetic Biosciences Inc Stock (XBIO) Company Profile
Name
Xenetic Biosciences Inc
Sector
Industry
Phone
781-778-7720
Address
945 CONCORD ST., FRAMINGHAM, MA
Compare XBIO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XBIO
Xenetic Biosciences Inc
|
3.38 | 7.47M | 2.98M | -2.68M | -2.29M | -1.6157 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Xenetic Biosciences Inc Stock (XBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-20 | Initiated | Maxim Group | Buy |
Xenetic Biosciences Inc Stock (XBIO) Latest News
Investment Report: Can Xenetic Biosciences Inc maintain sales growth2026 Valuation Update & Breakout Confirmation Alerts - baoquankhu1.vn
Published on: 2026-04-13 21:59:57 - baoquankhu1.vn
History Review: Is Xenetic Biosciences Inc stock good for income investors2026 Patterns & Fast Exit and Entry Trade Guides - baoquankhu1.vn
Sectors Review: Is Xenetic Biosciences Inc stock undervalued right nowTrade Risk Summary & Verified Momentum Watchlists - baoquankhu1.vn
Loss Report: Is Xenetic Biosciences Inc a potential multi baggerWeekly Risk Report & Risk Controlled Stock Alerts - baoquankhu1.vn
XBIO PE Ratio & Valuation, Is XBIO Overvalued - Intellectia AI
XBIO.WS (Xenetic Biosciences) PB Ratio : (As of Apr. 04, 2026) - gurufocus.com
Highs Report: Is now the right time to enter Xenetic Biosciences Inc2026 PreEarnings & Weekly High Conviction Ideas - baoquankhu1.vn
Xenetic Biosciences, Inc. (NASDAQ:XBIO) Short Interest Update - Defense World
Published on: 2026-03-27 18:33:00 - baoquankhu1.vn
Aug Volume: Is Xenetic Biosciences Inc on track to beat earningsQuarterly Growth Report & Verified Short-Term Plans - baoquankhu1.vn
Analyst Calls: Can Xenetic Biosciences Inc be recession proof2026 Valuation Update & Long-Term Safe Investment Ideas - baoquankhu1.vn
Xenetic (XBIO) Reports Increased Revenue and Advances Clinical D - GuruFocus
Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results - Bitget
[8-K] Xenetic Biosciences, Inc. Reports Material Event | XBIO SEC FilingForm 8-K - Stock Titan
Cancer biotech Xenetic grows Takeda royalties to $3M, trims costs - Stock Titan
Xenetic Biosciences: Fourth Quarter Financial Results Overview - Bitget
Xenetic Biosciences 2025 Annual Report: Advancing DNase Immuno-Oncology Technology for Solid Tumors and Strategic Business Developments - Minichart
Xenetic Biosciences: Q4 Earnings Snapshot - KTVB
XBIO: Revenue up 19%, net loss narrows, DNase oncology focus, strategic review underway - TradingView
Xenetic Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
XBIO SEC FilingsXenetic Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Risk On: Can Xenetic Biosciences Inc be recession proofWeekly Profit Summary & Daily Oversold Stock Bounce Ideas - baoquankhu1.vn
Big Money Moves: Is Xenetic Biosciences Inc stock a value trapJuly 2025 Retail & Community Consensus Stock Picks - baoquankhu1.vn
Published on: 2026-03-07 03:26:22 - baoquankhu1.vn
Xenetic Biosciences adjourns 2025 annual meeting - MSN
Can Xenetic Biosciences Inc be recession proofTrade Performance Summary & Fast Gain Stock Tips - baoquankhu1.vn
XBIO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Analyst Downgrade: Can Xenetic Biosciences Inc be recession proofQuarterly Investment Review & Safe Capital Allocation Plans - baoquankhu1.vn
XBIO Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results - Montgomery Advertiser
XBIO Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Xenetic Biosciences Inc. (XBIO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
XBIO Should I Buy - Intellectia AI
Xenetic Biosciences, Inc. (NASDAQ:XBIO) Sees Large Increase in Short Interest - Defense World
Trading Recap: Is AMKR stock a value trapWeekly Loss Report & Growth Focused Stock Reports - baoquankhu1.vn
Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting - Independent Mail
Is Xenetic Biosciences Inc stock undervalued right now2025 Sector Review & Technical Buy Zone Confirmations - baoquankhu1.vn
Aug Analyst Calls: Is now the right time to enter Xenetic Biosciences IncJuly 2025 Pullbacks & Safe Entry Trade Reports - baoquankhu1.vn
Technical Analysis: Is VRMEW affected by consumer sentimentChart Signals & Growth Focused Stock Pick Reports - baoquankhu1.vn
Can Xenetic Biosciences Inc. stock deliver strong Q4 earnings2025 Retail Activity & Safe Swing Trade Setup Alerts - mfd.ru
Investor Mood: Whats the outlook for Xenetic Biosciences Incs sectorWeekly Risk Summary & Weekly Stock Breakout Alerts - baoquankhu1.vn
Trend Report: Whats the profit margin of Xenetic Biosciences Inc2025 EndofYear Setup & Community Verified Swing Trade Signals - baoquankhu1.vn
Aug PreEarnings: Can Xenetic Biosciences Inc maintain sales growthWeekly Stock Report & Growth Oriented Trade Recommendations - baoquankhu1.vn
Support Test: Is National Energy Services Reunited Corp gaining market shareMarket Growth Report & AI Driven Stock Price Forecasts - baoquankhu1.vn
Can Xenetic Biosciences Inc. be recession proofGDP Growth & Growth Focused Stock Pick Reports - mfd.ru
How cyclical is Xenetic Biosciences Inc.’s revenue streamEarnings Overview Report & Smart Money Movement Tracker - mfd.ru
Is Xenetic Biosciences Inc. stock undervalued right nowRate Cut & Real-Time Price Movement Reports - mfd.ru
Xenetic Biosciences appoints James Parslow as interim CEO - Intellectia AI
Renaissance holds 7.79% of Xenetic Biosciences (XBIO) shares - Stock Titan
Aug Drivers: Can Xenetic Biosciences Inc be recession proofTrade Performance Summary & Long-Term Safe Investment Plans - baoquankhu1.vn
Xenetic Biosciences Inc Stock (XBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):